BR112014031866A2 - Composição farmacêutica intramamária para utilização no tratamento ou prevenção da mastite em um mamífero não humano e composição farmacêutica de fosfomicina e de pelo menos um anti-microbiano - Google Patents

Composição farmacêutica intramamária para utilização no tratamento ou prevenção da mastite em um mamífero não humano e composição farmacêutica de fosfomicina e de pelo menos um anti-microbiano

Info

Publication number
BR112014031866A2
BR112014031866A2 BR112014031866A BR112014031866A BR112014031866A2 BR 112014031866 A2 BR112014031866 A2 BR 112014031866A2 BR 112014031866 A BR112014031866 A BR 112014031866A BR 112014031866 A BR112014031866 A BR 112014031866A BR 112014031866 A2 BR112014031866 A2 BR 112014031866A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
antimicrobial
treating
intramammary
fosfomycin
Prior art date
Application number
BR112014031866A
Other languages
English (en)
Inventor
Heinz-Georg Wetztein
Kristine Fraatz
Robrecht Froyman
Wolfgang Wiehl
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48672650&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014031866(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of BR112014031866A2 publication Critical patent/BR112014031866A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

composição farmacêutica intramamária para utilização no tratamento ou prevenção da mastite em um mamífero não humano e composição farmacêutica de fosfomicina e de pelo menos um antimicrobiano. a presente invenção refere-se a uma composição farmacêutica e a métodos de tratamento e/ou prevenção da mastite em mamíferos não humanos. mais particularmente, a presente invenção refere-se ao tratamento de mastite em vacas. a composição farmacêutica contém uma mistura de ácido fosfónico e pelo menos um anti-microbiano.
BR112014031866A 2012-06-29 2013-06-25 Composição farmacêutica intramamária para utilização no tratamento ou prevenção da mastite em um mamífero não humano e composição farmacêutica de fosfomicina e de pelo menos um anti-microbiano BR112014031866A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261666312P 2012-06-29 2012-06-29
PCT/EP2013/063310 WO2014001353A1 (en) 2012-06-29 2013-06-25 Pharmaceutical compositions and treatment of mastitis

Publications (1)

Publication Number Publication Date
BR112014031866A2 true BR112014031866A2 (pt) 2022-02-01

Family

ID=48672650

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014031866A BR112014031866A2 (pt) 2012-06-29 2013-06-25 Composição farmacêutica intramamária para utilização no tratamento ou prevenção da mastite em um mamífero não humano e composição farmacêutica de fosfomicina e de pelo menos um anti-microbiano

Country Status (22)

Country Link
US (1) US10265330B2 (pt)
EP (1) EP2866812B1 (pt)
JP (1) JP6246804B2 (pt)
KR (1) KR20150030707A (pt)
CN (2) CN104379151A (pt)
AR (1) AR091603A1 (pt)
AU (1) AU2013283375B2 (pt)
BR (1) BR112014031866A2 (pt)
CA (1) CA2877794C (pt)
CL (1) CL2014003503A1 (pt)
CO (1) CO7240376A2 (pt)
CR (1) CR20140594A (pt)
DO (1) DOP2014000300A (pt)
EC (1) ECSP14033371A (pt)
HK (1) HK1206623A1 (pt)
IL (1) IL235768A0 (pt)
MX (1) MX368153B (pt)
NZ (1) NZ702087A (pt)
PE (1) PE20150199A1 (pt)
PH (1) PH12014502864A1 (pt)
RU (1) RU2659430C2 (pt)
WO (1) WO2014001353A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9737047B2 (en) 2011-03-22 2017-08-22 Ccd Holdings Llc Method for the treatment, control, minimization, and prevention of bovine mastitis
US8757092B2 (en) 2011-03-22 2014-06-24 Eco-Composites Llc Animal bedding and associated method for preparing the same
KR20150030707A (ko) 2012-06-29 2015-03-20 바이엘 애니멀 헬스 게엠베하 약학 조성물 및 유방염 치료
MX2015010191A (es) * 2013-02-08 2016-08-03 Luoda Pharma Pty Ltd Metodos para tratar infecciones microbianas, incluyendo mastitis.
AU2014237232B9 (en) 2013-03-15 2018-02-01 Genzyme Corporation Amine functional polyamides
JP6514211B2 (ja) 2013-09-16 2019-05-15 ゾエティス・サービシーズ・エルエルシー 薬物を連続して送達するためのアセンブリ及び関連方法
JP2016088918A (ja) * 2014-11-11 2016-05-23 大山乳業農業協同組合 ***炎治療・予防用組成物、並びに、***炎の治療・予防方法
PT3124016T (pt) * 2015-07-31 2019-12-13 Univ Warszawski Medyczny Composição de emulsão antipsoriática que compreende cefazolina
US10772900B2 (en) * 2016-07-27 2020-09-15 The Trustees Of The University Of Pennsylvania Drug target for treating veterinary infections and methods of using same
CN114126609B (zh) * 2019-07-11 2024-01-02 株式会社赛轮制药 原藻病的新型治疗剂
CA3205453A1 (en) * 2020-12-24 2022-06-30 Intervet International B.V. Methods of treating mastitis with an orthosomycin antimicrobial compound
RU2762088C1 (ru) * 2021-05-05 2021-12-15 Федеральное государственное бюджетное научное учреждение "Всероссийский научно-исследовательский ветеринарный институт патологии, фармакологии и терапии" (ФГБНУ "ВНИВИПФиТ") Способ лечения мастита у коров
CN113368043A (zh) * 2021-06-11 2021-09-10 吉林大学 一种复方阿莫西林***注入剂及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4034099A (en) * 1974-03-29 1977-07-05 The Upjohn Company Compositions and method for treating mastitis in milk animals
US4210635A (en) * 1978-02-15 1980-07-01 Fujisawa Pharmaceutical Co., Ltd. Antibacterial composition
US4330529A (en) * 1978-02-15 1982-05-18 Fujisawa Pharmaceutical Co., Ltd. Antibacterial composition
JPS62129217A (ja) * 1985-12-02 1987-06-11 Fujisawa Pharmaceut Co Ltd 医薬用殺菌組成物
EP1001778B1 (en) * 1997-07-29 2003-07-09 Kaneka Corporation Use of a rifamycin derivative for treating mastitis in a domestic animal
KR100807414B1 (ko) * 2003-07-31 2008-02-25 파마시아 앤드 업존 캄파니 엘엘씨 유선염 및 귀 장애의 치료를 위한 분산성 약학 조성물
DE102004054873A1 (de) * 2004-11-12 2006-05-18 Bayer Healthcare Ag Behandlung von Mastitis
EP2018864A1 (en) 2007-07-23 2009-01-28 Biomet Deutschland GmbH Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition
CN101744827B (zh) * 2008-12-15 2012-05-30 天津中敖生物科技有限公司 治疗鸡大肠杆菌的药物组合物及其制备方法、应用
US8449916B1 (en) * 2009-11-06 2013-05-28 Iowa State University Research Foundation, Inc. Antimicrobial compositions and methods
EP2404601A1 (en) 2010-07-06 2012-01-11 BioAgency AG New drug combinations for the treatment of Malaria
CN101879172B (zh) * 2010-07-13 2012-07-18 杨建彬 头孢噻呋钠复方制剂
EA021846B1 (ru) 2011-05-11 2015-09-30 ЛИМОНОВ, Виктор Львович Фармацевтическая композиция антибактериального действия для парентерального применения, способ ее получения
KR20150030707A (ko) 2012-06-29 2015-03-20 바이엘 애니멀 헬스 게엠베하 약학 조성물 및 유방염 치료

Also Published As

Publication number Publication date
RU2015102562A (ru) 2016-08-20
HK1206623A1 (en) 2016-01-15
CL2014003503A1 (es) 2015-05-04
IL235768A0 (en) 2015-01-29
WO2014001353A1 (en) 2014-01-03
CN104379151A (zh) 2015-02-25
US10265330B2 (en) 2019-04-23
PH12014502864A1 (en) 2015-02-23
MX2014015631A (es) 2015-04-09
AR091603A1 (es) 2015-02-18
EP2866812B1 (en) 2017-10-04
US20150164926A1 (en) 2015-06-18
CO7240376A2 (es) 2015-04-17
CN110522914A (zh) 2019-12-03
AU2013283375B2 (en) 2018-04-26
NZ702087A (en) 2016-12-23
KR20150030707A (ko) 2015-03-20
AU2013283375A1 (en) 2014-12-18
CR20140594A (es) 2015-02-06
CA2877794C (en) 2020-08-04
RU2659430C2 (ru) 2018-07-02
JP2015521644A (ja) 2015-07-30
MX368153B (es) 2019-09-20
PE20150199A1 (es) 2015-01-31
JP6246804B2 (ja) 2017-12-13
DOP2014000300A (es) 2015-07-15
ECSP14033371A (es) 2015-09-30
EP2866812A1 (en) 2015-05-06
CA2877794A1 (en) 2014-01-03

Similar Documents

Publication Publication Date Title
BR112014031866A2 (pt) Composição farmacêutica intramamária para utilização no tratamento ou prevenção da mastite em um mamífero não humano e composição farmacêutica de fosfomicina e de pelo menos um anti-microbiano
BR112015022417A2 (pt) métodos e composições para inibição de proteínas contendo bromodomínio
EA201500365A1 (ru) Комбинация регорафениба и ацетилсалициловой кислоты для лечения рака
BR112015021970A2 (pt) composições à base de nanopartículas
BR112013032774A2 (pt) métodos para tratar e prevenir infecções por staphylococcus aureus e condições associadas
BR112016021648A2 (pt) novos compostos
BR112014025041B8 (pt) Composição farmacêutica
BR112015003729A8 (pt) Composto de fórmula estrutural i; composição farmacêutica; método de tratamento de uma doença mediada por caminho do hif; método de tratamento de uma doença causada por proliferação anormal de células; e método para alcançar um efeito em um paciente
CO6741223A2 (es) Derivados de azetidina útiles para el tratamiento de enfermedades metabólicas e inflamatorias
WO2012125408A8 (en) Pegylated apelin and uses thereof
BR112015029367A2 (pt) terapia combinada compreendendo oxazolidinona-quinolonas para uso no tratamento de infecções bacterianas
EA201791363A1 (ru) Пиразолопиридинамины в качестве ингибиторов mknk1 и mknk2
EA201591618A1 (ru) Замещенные имидазопиридазины
BR112014019399A2 (pt) métodos de tratamento da fibrose
EA201600398A1 (ru) Тиенопиримидины в качестве ингибиторов mknk1 и mknk2
BR112014028654A2 (pt) composições de complexo de quelato de oligonucleotídeo-polipeptídeo e métodos
BR112015011798A2 (pt) métodos e composições para tratar doenças neurodegenerativas
PH12016501814A1 (en) Inhibitors of the wnt signalling pathways
BR112014024033A8 (pt) Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes
BR112015000275A2 (pt) utilização de um extrato de mirta como agente anti-biopelícula face p. acnes
BR112014017587A8 (pt) métodos e formulações para o tratamento de deficiências de ácido siálico
BR112014009760A8 (pt) análogos de ácido siálico
BR112016008267A2 (pt) Composição para prevenir ou tratar esclerose lateral amiotrófica usando duas ou mais isoformas de fator de crescimento de hepatócito
BR112018002763A2 (pt) método para cicatrização de ferimentos
EP3064203A4 (en) Pharmaceutical composition for preventing or treating liver diseases, containing plasmalogen precursor, plasmalogen or plasmalogen analog as effective component

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]